 |
|
|
| |
Drug-Related Neuropsychiatric Adverse Events Across Phase 3/3b Studies of Long-Acting Cabotegravir + Rilpivirine Through Week 48
|
| |
| |
Emilie Elliot1, Paula Teichner2, Samia Dakhia1, Joseph W. Polli2, Parul Patel2, Louise Garside3, Sri Byrapuneni4, Shanker Thiagarajah5, Ronald D'Amico2,
Rodica Van Solingen-Ristea6, Eileen Birmingham7, Bryan Baugh8, Jean van Wyk1
1ViiV Healthcare, Brentford, United Kingdom; 2ViiV Healthcare, Research Triangle Park, NC, United States; 3PHASTAR, Macclesfield, United Kingdom; 4Parexel International, Research Triangle Park, NC, United States; 5GSK, London, United Kingdom; 6Janssen Research & Development, Beerse, Belgium; 7Janssen Research & Development LLC, Raritan, NJ, United States; 8Janssen Research & Development, Titusville, NJ, United States
|
| |
|
|
|
|
|
